Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $576K | $479K | $625K | $710K | $145K | $1.01M | $1.35M | $477K | $58.0K | $0.00 |
| Revenue growth | — | -16.8% | 30.5% | 13.6% | -79.6% | 600.0% | 33.2% | -64.7% | -87.8% | -100.0% |
| Operating income | -$7.61M | -$12.4M | -$14.1M | -$14.2M | -$15.5M | -$12.6M | -$11.9M | -$11.6M | -$8.00M | -$8.28M |
| Operating margin | -1320.8% | -2589.8% | -2256.3% | -2001.8% | -10709.7% | -1244.3% | -880.3% | -2441.1% | -13794.8% | — |
| Net income | -$10.3M | -$12.3M | -$14.0M | -$14.7M | -$15.0M | -$12.6M | -$11.9M | -$11.6M | -$7.95M | -$8.23M |
| Net margin | -1789.9% | -2569.5% | -2237.9% | -2071.7% | -10347.6% | -1243.6% | -880.7% | -2425.8% | -13700.0% | — |
| EPS (diluted) | -$1.23 | -$2.90 | -$3.28 | -$2.61 | -$1.48 | -$0.75 | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.52M | -$8.67M | -$11.1M | -$9.45M | -$12.4M | -$10.4M | -$10.6M | -$9.97M | -$7.89M | -$7.44M |
| Capital expenditures | — | $136K | $66.0K | $146K | $32.0K | $116K | $70.0K | $12.0K | $6.00K | $7.00K |
| Free cash flow | — | -$8.81M | -$11.1M | -$9.59M | -$12.4M | -$10.5M | -$10.6M | -$9.99M | -$7.89M | -$7.44M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $21.4M | $12.7M | $5.36M | $5.58M | $21.4M | $12.9M | $7.36M | $1.10M | $2.37M | $2.50M |
| Total assets | $22.1M | $13.5M | $6.42M | $7.68M | $23.4M | $15.7M | $9.79M | $2.99M | $3.72M | $3.41M |
| Total liabilities | $1.50M | $2.41M | $2.63M | $5.31M | $4.25M | $5.34M | $4.90M | $4.59M | $2.89M | $2.52M |
| Shareholders' equity | $20.6M | $11.1M | $3.79M | $2.37M | $19.2M | $10.4M | $4.89M | -$1.60M | $837K | $895K |
| Retained earnings | -$60.1M | -$72.5M | -$86.4M | -$101M | -$116M | -$129M | -$141M | -$152M | -$160M | -$168M |
| Shares (wtd avg diluted) | 38.1M | 38.2M | 4.85M | 6.83M | 16.3M | 16.9M | 17.7M | 1.41M | 2.74M | 6.67M |
Every figure is extracted from BioCardia, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.